BIOEDGE

Biological EDGE

Buy Now

“Meticulous research. Penetrating analysis. A solid framework for change.”  — Dr. Michael J. Krentz

Biological EDGE

Biohacking Starts With NO

Buy Now

“I used to override my body. Now I listen. The difference is stunning.”— Michael Broder

Biohacking Starts With NO
Mental and Cognitive Health

Mental and Cognitive Health Library

Every article, presentation, spotlight, and news item we've tagged to Mental and Cognitive Health.

AllLibraryArticlesPresentationsSpotlightsNews

Showing 97–120 of 127

LT WireMar 19, 2026

ADDF launches new phase of $150m Alzheimer’s diagnostics accelerator

The Alzheimer's Drug Discovery Foundation has committed an additional $50 million to its Diagnostics Accelerator program, now totaling $150 million, to advance blood-based biomarkers, multi-marker panels, and AI-driven diagnostic tools for Alzheimer's disease. This investment targets earlier detection and disease monitoring to enable preventive interventions and combination therapies before irreversible neurodegeneration occurs.

Longevity.TechnologyFeb 18, 2026

Menopause linked to brain structure shifts

Post-menopausal women show measurable reductions in gray matter volume within memory and emotion-regulating brain regions, correlating with increased anxiety, depression, and sleep disruption. This structural shift represents a neuroendocrine transition point with downstream implications for cognitive resilience and cardiometabolic risk in aging.

Nature - npj AgingMar 12, 2026

Testing the redox theory of aging under parasitism

Parasitic infection accelerates oxidative stress and aging markers in host organisms, providing empirical support for redox-based aging mechanisms. This finding illuminates how chronic pathogenic burden compounds systemic dysfunction and accelerates cellular deterioration through reactive oxygen species accumulation.

Nature - npj AgingMar 13, 2026

Urbanization, environment, and inflammaging: insights from sub-Saharan Africa

Urban environments in sub-Saharan Africa show accelerated inflammaging—chronic, low-grade systemic inflammation associated with aging—driven by environmental stressors including air pollution, pathogenic load, and dietary shifts. This research identifies modifiable environmental and lifestyle factors that influence the rate of immunological aging independent of chronological age.

Longevity.TechnologyApr 30, 2026

Rafael Holdings gains exclusive MIT Alzheimer’s patent

Rafael Holdings secured exclusive MIT patent rights for cyclodextrin-based molecules targeting ApoE4-positive Alzheimer's disease by restoring cholesterol transport between brain cells. This represents a shift from amyloid-clearance paradigms toward addressing the cellular infrastructure that prevents pathological buildup in the first place.

SAGE Research on AgingMay 4, 2026

Shared Experience of Physical Vitality and Social Participation Among Caregiving Dyads: Comparing Dyads With and Without Dementia

Caregiving relationships that maintain shared physical activity and social engagement protect against isolation and functional decline in aging adults, with dementia-affected dyads showing particular vulnerability. The structure of caregiving partnerships—whether they preserve mutual participation or devolve into dependency—predicts health trajectories independent of diagnosis.

Nature - npj AgingApr 7, 2026

Aging effects on emotionality, cognition and brain mononuclear cells in Sprague-Dawley rats of both sexes

Aging in rats produces sex-dependent changes in emotional regulation, cognitive function, and brain immune cell populations, with females showing greater cognitive decline and males exhibiting more pronounced emotional dysregulation. These findings suggest that neuroinflammation and immune cell dynamics contribute to cognitive and emotional aging, with implications for understanding sex-specific vulnerabilities in human neurodegenerative conditions.

LifeSpan.ioApr 10, 2026

Affecting a Signaling Pathway Alleviates Alzheimer’s in Mice

Somatostatin overexpression in neurons reduces microglial activation and inflammatory signaling while enhancing amyloid-β clearance in an Alzheimer's mouse model. Existing drugs targeting this pathway suggest translational potential for addressing neuroinflammation in cognitive decline.

Longevity.TechnologyMar 25, 2026

Autophagy angle sharpens Anavex’s investment case for Alzheimer’s

Research published in PNAS Nexus proposes that autophagy dysfunction—a slowdown in cellular recycling—precedes amyloid and tau pathology in Alzheimer's disease. This upstream mechanism shifts the therapeutic target from clearing late-stage debris to restoring the cell's natural cleanup capacity earlier in disease progression.

Nature AgingFeb 27, 2026

Structural signature of plasma proteins classifies the status of Alzheimer’s disease

Plasma protein structural changes—not just abundance—distinguish Alzheimer's disease progression and predict disease status independent of traditional genetic risk markers. This approach identifies conformational biomarkers that shift with disease stage, genotype, and sex, offering a measurable window into pathological mechanisms before cognitive decline becomes severe.

Longevity.TechnologyFeb 24, 2026

Nanoplastics found in the brain raise new aging questions

Nanoplastics have been detected in human brain tissue and show correlation with neurodegenerative disease severity and accelerated aging markers. The particles' ability to cross biological barriers and interact with pathological proteins suggests chronic, low-level exposure represents a longevity risk distinct from acute toxicity.

Longevity.TechnologyApr 10, 2026

CorTec receives FDA breakthrough device designation

The FDA granted Breakthrough Device Designation to CorTec's Brain Interchange, a fully implantable wireless brain-computer interface that uses closed-loop neural recording and adaptive stimulation to restore motor function in chronic stroke patients. Early clinical data show meaningful upper-limb recovery in patients whose progression had plateaued under conventional therapy.

Longevity.TechnologyMar 24, 2026

Blarcamesine links functional and cognitive outcomes in AD-004 trial

Blarcamesine demonstrated a measurable correlation between MRI-detected preservation of brain volume and slowing of cognitive decline in early Alzheimer's disease, with particularly strong outcomes in a genetically defined subpopulation. Long-term data suggest a potential delay in functional deterioration of approximately 18 months over 33 months of treatment.

LT WireApr 15, 2026

Anavex highlights shared autophagy biology in autism and Alzheimer’s

Anavex presents evidence linking autism spectrum disorder and Alzheimer's disease through impaired autophagy and synaptic dysfunction, proposing that restoring cellular clearance pathways via their compound Blarcamesine may address both conditions. The finding connects neurodevelopmental and neurodegenerative disease through a shared cellular mechanism, with epidemiological data showing autistic adults face substantially elevated dementia risk.

Nature - npj AgingMar 11, 2026

Stroke in persistent chronic kidney disease condition alters innate-immunity to escalate mitochondrial dysfunction and aging

Stroke in the context of chronic kidney disease triggers immune dysregulation that accelerates mitochondrial dysfunction and aging processes. This cascade reveals how organ system failure in one area can compromise cellular energy production and immunity simultaneously, with significant implications for longevity in populations with renal compromise.

Longevity.TechnologyMar 25, 2026

Brain health ‘collaboratory’ focuses on non-invasive Alzheimer’s therapy

Cognito Therapeutics and Ochsner Health are partnering to test Spectris, a non-invasive neuromodulation device that delivers synchronized light and sound stimulation to restore gamma oscillations disrupted in Alzheimer's disease. Early evidence shows the approach slows cognitive decline and reduces brain volume loss, with the collaboration designed to evaluate real-world clinical implementation across diverse healthcare settings.

LifeSpan.ioMar 19, 2026

Using mRNA to Fight Tau Aggregation in Alzheimer’s

Researchers developed a lipid nanoparticle that delivers mRNA encoding TRIM11, a natural ligase that disaggregates tau tangles, across the blood-brain barrier in mouse models of Alzheimer's disease. Treatment produced sustained cognitive and behavioral restoration comparable to wild-type mice, with reduction in tau pathology and neuroinflammatory markers.

Longevity.TechnologyMar 10, 2026

The mouth-body connection: why oral health matters for longevity

Oral health functions as a systemic gateway affecting breathing mechanics, sleep quality, inflammation, and metabolism rather than existing as an isolated dental concern. Optimizing breathing patterns, airway function, and oral microbiota through evidence-based dental and postural interventions produces measurable improvements in cardiovascular health, sleep architecture, and immune function.

Wiley Aging CellMar 17, 2026

The Adiponectin‐PP2A Pathway Confers Cognitive Benefits of Physical Exercise Against Chronic Stress‐Induced Tau Hyperphosphorylation in the Hippocampus

Physical exercise elevates circulating adiponectin, which activates PP2A phosphatase in the hippocampus to reduce pathological tau phosphorylation and restore cognitive function under chronic stress. This mechanism operates independently of adiponectin's other metabolic functions and identifies a direct molecular pathway by which exercise protects against Alzheimer's-like neuropathology.

SAGE Research on AgingMar 16, 2026

Cross-Sectional and Longitudinal Associations Among Loneliness, Depression/Anxiety, and the Subjective and Chronological Age Difference in Older Adults

Loneliness and depression/anxiety in older adults correlate with feeling older than one's chronological age, with longitudinal evidence suggesting emotional distress may accelerate subjective aging. This relationship has direct implications for how psychological states influence biological aging trajectories.

LifeSpan.ioApr 10, 2026

Affecting a Signaling Pathway Alleviates Alzheimer’s in Mice

Overexpression of somatostatin, a neuropeptide normally produced by neurons, reduces microglial activation and amyloid-β burden while improving cognitive function in an Alzheimer's disease mouse model. The finding identifies a previously untested communication pathway between neurons and immune cells that becomes dysregulated in the disease and offers a target for existing pharmaceuticals.

LifeSpan.ioMar 13, 2026

Gut Bacteria Might Affect Cognition via the Vagus Nerve

Age-related cognitive decline involves microbiome remodeling, with Parabacteroides goldsteinii identified as a primary driver that suppresses neuronal activation in the hippocampus via the vagus nerve. Antibiotic treatment reverses the cognitive deficit even after it develops, establishing the microbiome as a modifiable mechanism rather than an irreversible consequence of aging.

Peter Attia MDMar 16, 2026

#384 – Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer’s prevention

Obicetrapib, a CETP inhibitor, demonstrates cardiovascular benefits and potential neuroprotective effects against Alzheimer's disease—outcomes that distinguish it from four previous compounds in this drug class. The mechanism addresses both systemic lipid metabolism and cerebral amyloid pathology, making it relevant to multi-system longevity strategies.

LifeSpan.ioMar 20, 2026

Meat Consumption May Benefit APOE4 Carriers

A 15-year Swedish cohort study found that unprocessed meat consumption was associated with preserved cognitive trajectory and reduced dementia risk in APOE ε4 carriers, effectively neutralizing the genotype's established cognitive penalty at higher intake levels. This finding challenges the assumption that ε4 carriers universally benefit from plant-forward diets and suggests ancestral dietary patterns may interact with genetic risk architecture in ways that modern nutritional guidelines do not account for.